tbuckley/cabot-search huggingface dataset:
Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas.
Authors: Gita Suneja, Meredith S. Shiels, Sharon K. Melville, Melanie A. Williams, Ramesh Rengan, Eric A. Engels
Journal: Journal of Clinical Oncology (2012)

6070 Background: HIV-infected (HIV+) people are at elevated risk for lung cancer and have higher mortality following lung cancer diagnosis than uninfected (HIV-) individuals. The disparity in survival is partly due to advanced stage at diagnosis, but it is unclear whether HIV+ people with lung cancer are less likely to receive cancer treatment, which could worsen survival. Methods: We included adults ≥ 18 years of age with lung cancer reported to the Texas cancer registry (N=156,930). HIV status was determined by linkage with the enhanced Texas HIV/AIDS Reporting System. We compared HIV+ and HIV- lung cancer cases with respect to demographic and clinical characteristics. For non-small cell lung cancer (NSCLC) cases, we identified predictors of cancer treatment (surgery, radiation, and chemotherapy) using logistic regression. We used Cox regression to evaluate the effects of HIV and treatment on lung cancer-specific mortality. Results: Compared with HIV- lung cancer cases (N=156,593), HIV+ lung cancer cases (N=337) were more likely to be young, non-Hispanic black, male, and to have distant stage disease (53.7% vs. 44.4%). HIV+ cases were less likely to receive cancer treatment than HIV- cases (60.3% vs. 77.5%; odds ratio 0.39, 95%CI 0.30-0.52 after adjustment for diagnosis year, age, sex, race, stage, and histologic subtype). In Cox models adjusted for these variables, both HIV infection (hazard ratio [HR] 1.34, 95%CI 1.15-1.56) and lack of cancer treatment (HR 1.69, 95%CI 1.66-1.72) were associated with higher lung cancer-specific mortality. After adjustment for cancer treatment, the association between HIV and lung cancer mortality was attenuated (HR 1.25, 95%CI 1.06-1.47). The association between HIV and lung cancer-specific mortality was stronger among untreated lung cancer cases (HR 1.32, 95%CI 1.01-1.72) than treated cases (adjusted HR 1.16, 95%CI 0.94-1.43; p-interaction=0.34). Conclusions: In this population-based study, HIV+ people with NSCLC were less likely to be treated for lung cancer than their HIV- counterparts. This lack of treatment may be partly responsible for higher cancer-related mortality in HIV+ cases. Further investigation is needed to understand disparities in cancer treatment for HIV+ people.
A STRESS REDUCTION, MEDITATION AND MINDFULNESS PROGRAM IN STABLE PATIENTS WITH CHRONIC HEART FAILURE
Authors: Vaisnava Cavalcante, Evandro Mesquita, Ana Carla Cavalcante, Jacqueline Miranda, Glaucio Bandeira, Isabela Venancio, Lais Guimaraes, Nathalia Correa, Paola Jardim, Angela Dantas, Joao Tress
Journal: Journal of the American College of Cardiology (2020)
Hospice Utilization in Elderly Patients With Brain Metastases
Authors: Elie K Mehanna, Paul J Catalano, Daniel N Cagney, Daphne A Haas-Kogan, Brian M Alexander, James A Tulsky, Ayal A Aizer
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background Brain metastases are associated with considerable morbidity and mortality. Integration of hospice at the end of life offers patients symptom relief and improves quality of life, particularly for elderly patients who are less able to tolerate brain-directed therapy. Population-level investigations of hospice utilization among elderly patients with brain metastases are limited. Methods Using the Surveillance, Epidemiology and End Results–Medicare database for primary cancer sites that commonly metastasize to the brain, we identified 50 148 patients (aged 66 years and older) diagnosed with brain metastases between 2005 and 2016. We calculated the incidence, timing, and predictors of hospice enrollment using descriptive techniques and multivariable logistic regression. All statistical tests were 2-sided. Results The incidence of hospice enrollment was 71.4% (95% confidence interval [CI] = 71.0 to 71.9; P &amp;lt; .001), a rate that increased over the study period (P &amp;lt; .001). The odds of enrollment for black (odds ratio [OR] = 0.76, 95% CI = 0.71 to 0.82; P &amp;lt; .001), Hispanic (OR = 0.80, 95% CI = 0.72 to 0.87; P &amp;lt; .001), and Asian patients (OR = 0.52, 95% CI = 0.48 to 0.57; P &amp;lt; .001) were substantially lower than white patients; men were less likely to be enrolled in hospice than women (OR = 0.78, 95% CI = 0.74 to 0.81; P &amp;lt; .001). Among patients enrolled in hospice, 32.6% (95% CI = 32.1 to 33.1; P &amp;lt; .001) were enrolled less than 7 days prior to death, a rate that was stable over the study period. Conclusions Hospice is used for a majority of elderly patients with brain metastases although a considerable percentage of patients die without hospice services. Many patients enroll in hospice late and, concerningly, statistically significant sociodemographic disparities exist in hospice utilization. Further investigations to facilitate targeted interventions addressing such disparities are warranted.
VENTRICULAR TACHYCARDIA SECONDARY TO NONISCHEMIC CARDIOMYOPATHY: A CASE WITH VARIABLE CLINICAL BURDEN DURING THE COURSE OF PREGNANCY
Authors: Satyaki Chakrabarty, Ioannis Koulouridis, Argyro Papafilippaki, Lucy Bayer-Zwirello, Lana Tsao
Journal: Journal of the American College of Cardiology (2020)
Relationship of Ki-67 proliferative index and metastatic tumor of breast cancer.
Authors: Kokoro Kobayashi, Yoshinori Ito, Akiko Ogiya, Naoya Gomi, Rie Horii, Shunji Takahashi, Kiyohiko Hatake, Futoshi Akiyama, Takuji Iwase
Journal: Journal of Clinical Oncology (2013)

e22190 Background: The metastatic breast tumor tends to be more aggressive with high proliferation, but this has not been proven in clinical sampling of metastatic tumors. Methods: Forty-eight patients who had histological specimens of both primary and metastatic sites of luminal breast cancer (ER and/or PgR positive and HER2 negative) were examined. We classified them as luminal A (LA) with Ki-67 labeling index of less than 14% and as luminal B (LB) with Ki-67 labeling index of more than 14%. We analyzed their overall survival (OS) and progression free survival (PFS) of 1st line treatment of each subtype of primary and metastatic tumors. Results: Subtypes of primary tumors and metastatic tumors were as follows; the primary tumor: LA; 34 patients (70.8%), LB; 14 (29.2%), metastatic tumors: LA; 21 (43.8%), LB; 27 (56.2%). Patients with LA of the primary tumor demonstrated statistically longer OS (LA; 72.5 months, LB 39.6 months, p=0.009). OS depended on the subtype of the primary tumor. In contrast, patients with LB of a metastatic tumor showed a statistically worse PFS (LA; 20.5 months, LB; 11.5 months, p=0.040). PFS of the 1st line treatment for MBC depended on the subtype of the metastatic tumor. Conclusions: The frequency of LB was increased on metastatic tumors and tended to acquire a higher proliferation index. This suggests that characterization of metastatic tumors could be better as an indicator of subsequent treatment for MBC. [Table: see text]
IMPACT OF PALLIATIVE CARE INVOLVEMENT ON OUTSIDE HOSPITAL TRANSFERS TO THE CARDIAC CRITICAL CARE UNIT IN A TERTIARY CARE CENTER: A RETROSPECTIVE REVIEW
Authors: Sonika Patel, Kiran Motwani, Xinyuan Ning, Safanah Siddiqui, Keneil Shah, Majed Alnabulsi, Kathrynn Robinett
Journal: Journal of the American College of Cardiology (2020)
Phase II study of vinorelbine and capecitabine as first-line treatment for metastatic breast cancer.
Authors: Wael El-Sadda, Inas Ibraheim Abdel Halim, Mohamed Abdel Aziz
Journal: Journal of Clinical Oncology (2013)

e12004 Background: Vinorelbine (V) and capecitabine (C) are likely to have a synergisitic interaction. Vinorelbine upregulates thymidine phosphorylase; a key enzyme in the conversion of capecitabine to active 5-FU in tumor tissue. Available phase II clinical data reports response rates ranging from 48-70% in first line metastatic breast cancer (MBC) for this combination. We evaluated the efficacy and safety of vinorelbine plus capecitabine in patients with MBC relapsing after adjuvant anthracycline based treatment. Methods: Sixty patients were enrolled between Oct 2008 through Dec 2010. All patients had measurable MBC relapse after adjuvant anthracycline and/or taxanes, WHO PS &lt; 2, adequate bone marrow, renal and hepatic functions. Patients received intravenous vinorelbine 25 mg/m 2 on day 1 and 8 and oral capecitabine 1000 mg/m 2 bid on days 1 to 14, cycles to be repeated every 3 weeks. Patients with PD went off the study while those with CR, PR or SD continued treatment for a maximum of 8 cycles. Results: Median age 54 years (range 35-67 years), Median WHO PS 0 (range 0-1). Previous adjuvant therapy anthracycline (100%) and hormone therapy (60%). Median disease free interval was 6 months. Main metastatic sites were lung (40%), liver (25%), bone (40%) skin (35%), and lymph nodes (35%). Twenty five percent of patients had one metastatic site, 60% had two sites, 10% had three sites and 5% had more than three sites. The total number of cycles delivered was 441 with a median number of cycles/patients of 7 (range 3-8). An objective tumor response was achieved in 36 pts (60%), complete response (CR) in 6 pts (10%), 12 pts (20%) had stable disease (SD). After a follow up period of 6-36 months, the median time to progression and median survival were 14 and 23 months, respectively. No WHO G4 toxicities were noted, 3 pts (5%) developed G3 neutropenia and one patient (1.7%) developed G3 hand and foot syndrome. G2 anemia, neutropenia and diarrhea were reported in 2 pts (3.3%), 3 pts (5%) and 6 pts (10%), respectively. Conclusions: The combination of vinorelbine and capecitabine showed significant efficacy and mild toxicity as a first-line treatment for patients with metastatic breast cancer after failure of adjuvant anthracycline based therapy.
Epidermal growth factor receptor (EGFR) expression in colorectal cancer in Slovakia
Authors: T. Salek, J. Mardiak, F. Ondrias, J. Bodnar, L. Klimcakova
Journal: Journal of Clinical Oncology (2006)

20103 Background: EGFR is involved in the epidermal growth factor pathway that regulates cellular processes and is associated with the development of malignancy.EGFR targeted therapy could be an alternative option to improve clinical outcome in tumors with EGFR expression. Methods: From 09/2004 till 12/2005 we evaluated histologic specimens of 130 patients (89 male, 41 female) with colorectal cancer. EGFR expression was examined by immunohistochemistry using theEGFR Detection Kit (Dako Corporation) in paraffin-embedded colon/rectum tumors and graded as percentage of cells stained. Results: EGFR positivity (1% and more) was observed in 106 pts (81.5%) and EGFR negativity in 24 pts (18.5%). Median of positivity in percentage is 40 (1–95). Conclusions: The EGF receptor is overexpressed in many human tumors and is a promising therapeutic target. No significant financial relationships to disclose.
Graded prognostic assessment index for melanoma with brain metastases (MBM).
Authors: Kwabena Osei-Boateng, Vyshak Alva Venur, Saurabh Dahiya, Lingling Du, Rohan Garje, Paul Elson, Samuel T. Chao, Manmeet Singh Ahluwalia
Journal: Journal of Clinical Oncology (2013)

9086 Background: The Graded Prognostic Assessment (GPA) is a commonly used prognostic index in patients with brain metastases (BM). GPA for melanoma consists of Karnofsky Performance Scale (KPS) and the number of BM present. The purpose of this study was to evaluate the utility of GPA index in a contemporary cohort of patients (pts) with MBM at a single institution to predict Overall Survival (OS). Methods: With IRB approval, the Cleveland Clinic Brain Tumor and Neuro-Oncology Center’s database was used to identify pts with MBM treated between 2000-2012. The primary endpoint was OS from diagnosis of MBM. Cox proportional hazards models were used for data analysis. Stepwise variable selection was used to identify independent prognostic factors. Results: 90 MBM (51 females) median age 57 years (range 24-87) were included for analysis. The median number of BM was 2 (range, 1-11). KPS was 90-100(52%), 70-80 (43%) and &lt;70 (6%). Extracranial metastases was present in 75 patients (83%). Initial treatment included Stereotactic Radiosurgery (SRS) (49%), Whole Brain Radiotherapy (WBRT) (8%), WBRT + SRS (22%), WBRT + Surgery (S)(14%) and SRS + (S) (7%). Median OS was 7.8 months (95% C.I. 6.8-10.1). GPA was prognostic for OS ( p=0.01), however this was because pts with scores of 4 had worse outcomes (median 5.1months) than the other 3 groups, which had similar OS (median 9.0-12.8 months). In addition, number of BM was not associated with OS (p=0.19). In contrast, KPS (p=0.02), Liver (p=0.04) and hemorrhagic metastasis (p=0.02) were independently prognostic for OS. These factors can be used to derive a new prognostic index with 3 groups: Unfavorable, Intermediate and Favorable (see Table). Conclusions: GPA was prognostic for OS in pts with MBM, however separation of the groups was not clear. A new prognostic index consisting of KPS, liver and hemorrhagic metastases is proposed for MBM. [Table: see text]
SAFETY AND EFFICACY OF WATCHMAN DEVICE IMPLANTATION IN PATIENTS WITH VALVULAR HEART DISEASE A MULTICENTER STUDY
Authors: Amit Shrestha, Nachiket Apte, Arslan Naeem, Seth H. Sheldon, Matthew Earnest, Madhu Reddy, Michael Pierpoline, Aman Patel, Senthil Thambidorai, Arvindh Kanagasundram, Gregory Jackson, Jonathan Chandler, Christopher R. Ellis
Journal: Journal of the American College of Cardiology (2020)
14P Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
Authors: E. Castanon Alvarez, C. Vidal, L. Resano, A. Sánchez, M. Rodriguez, D. Salas, M. Fernandez de Sanmamed, J.M. López Picazo, L. Sanchez, J. Espinos, I. Melero, A. Gonzalez, M. Ponz-Sarvisé
Journal: Annals of Oncology (2020)
HEMODYNAMIC EFFECTS AND CARDIOVASCULAR SAFETY OF ONCE-DAILY ORAL AMPRELOXETINE (TD-9855), A NOREPINEPHRINE REUPTAKE INHIBITOR, IN HEALTHY ADULTS AND SUBJECTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION
Authors: Satish R. Raj, Lucy Norcliffe-Kaufmann, Whedy Wang, Brett Haumann, Ross Vickery
Journal: Journal of the American College of Cardiology (2020)
Prognostic factors and trends in outcome for small cell lung cancer over 20 years.
Authors: David Dawe, Sri Navaratnam, Marshall W. Pitz
Journal: Journal of Clinical Oncology (2012)

e17518 Background: There has been little change in the chemotherapeutic treatment of small cell lung cancer (SCLC) over the last 30 years but changes in radiotherapy have demonstrated a survival benefit in clinical trails. There is substantial disagreement in the literature on whether or not there has been an improvement in survival for SCLC patients and which patient characteristics serve as important prognostic factors. The majority of the data comes from the selective population of patients included in clinical trials, which do not necessarily reflect real world therapeutic effectiveness. Methods: Using the Manitoba Cancer Registry and Manitoba’s physician billing database, we extracted information on all patients receiving a pathologic diagnosis of SCLC in the Canadian province of Manitoba between Jan 1, 1985 and Dec 31, 2004. Linear regression and Cox proportional hazard regression were then used to determine trends in SCLC incidence, survival, sex distribution, treatment, and prognostic factors. Results: Over the course of the study, the number of cases of SCLC diagnosed each year decreased by 1.41 cases/year (p=0.007), due entirely to a decrease in male cases. The proportion of females increased by 1%/year (p&lt;0.001, 95% CI [0.007, 0.013]). In the whole study population, the proportion of patients receiving no antineoplastic treatment increased dramatically with age, from 11.7% in those ≤50 to 50.6% in patients &gt;80 years old (p&lt;0.001). There has been no change in 2 or 5-year survival (p&gt;0.05 at both time points), which is true for both males and females. Two-year survival was 12.7% for females vs 8% for males (p&lt;0.001), and at 5 years 5.3% of females vs 2.6% of males survive (p=0.002). Male sex was a negative prognostic factor with an adjusted hazard ratio of 1.27 (95% CI [1.16, 1.39]). Conclusions: Female sex is a positive prognostic factor in SCLC. In this population based trial, evolution of therapy over 20 years did not translate into improved survival. A further decline solely in the number of male cases may independently improve survival in the future.
CLO20-066: Comparative Efficacy, Safety and Acceptability of Single-Agent Poly (ADP-ribose) Polymerase (PARP) Inhibitors in BRCA Mutated HER2-Negative Metastatic or Advanced Breast Cancer: A Network Meta-Analysis
Authors: Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang, Xiaowei Qi
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-066: Comparative Efficacy, Safety and Acceptability of Single-Agent Poly (ADP-ribose) Polymerase (PARP) Inhibitors in BRCA Mutated HER2-Negative Metastatic or Advanced Breast Cancer: A Network Meta-Analysis" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Salvage prostatectomy for prostate cancer (CaP): Data from the Surveillance Epidemiology and End Results (SEER) database
Authors: P. A. Johnstone, M. Goodman, K. Ward, V. Assikis, K. Ogan
Journal: Journal of Clinical Oncology (2006)

4622 Recent randomized data have established adjuvant radiation therapy (RT) as a standard of care approach for appropriately selected high-risk CaP patients after radical prostatectomy (RP). However, data on salvage prostatectomy (SP; defined here as radical prostatectomy, total prostatectomy, and cystoprostatectomy) after definitive RT are available only in single-institution reports of limited patient numbers. We analyzed data from the SEER database for the period 1988–1997. Specifically analyzed were data for patients undergoing various combinations of surgery and RT with or without hormonal therapy (HT; defined as medications, surgical castration or both) for localized (Stage I/II) CaP. Patients with multiple primary cancers were excluded. Demographic data for each case included age and diagnosis, race and year of diagnosis. Cancer-related variables included SEER summary stage and grade. Treatment information included surgery, RT, HT, and sequence of surgery with radiation. Using follow-up data through 2002, post diagnosis observed survival (OS) and relative survival (RS; defined as observed survival divided by that expected in a national age-, gender-, and race-matched cohort) was examined in four treatment groups: 44 patients with RT prior to SP, 1376 patients with RT following RP, 36344 patients with RP alone, and 30717 patients with RT alone. Mortality across treatment categories was compared using a Cox proportionate hazard model controlling for age, year of diagnosis, race, HT, SEER registry, and grade. Although infrequently performed, SP provides for 10-year relative survival of 82%. After controlling for potential confounding factors, data for RT followed by SP showed no appreciable benefit compared to RT alone. [Table: see text] No significant financial relationships to disclose.
COMPARISON OF RIGHT VENTRICULAR STRAIN ANALYSIS TO ROUTINE ECHOCARDIOGRAHIC MEASURES FOR PROGNOSIS IN PATIENTS WITH CARDIAC AMYLOIDOSIS
Authors: Yuko S. Soyama, Kathleen Zhang, Peter Huntjens, Maria Karmpalioti, Ray Zhang, Daniel Lenihan, John Gorcsan
Journal: Journal of the American College of Cardiology (2020)
MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer.
Authors: Moisés Blanco-Calvo, Mar Haz-Conde, Teresa Rodríguez-Rigueiro, Angelica Figueroa, Margarita Reboredo, Vanessa Medina Villaamil, Maria J Lorenzo-Patiño, Francisco Arnal, Luis Antón-Aparicio, Guillermo Alonso-Jaudenes Curbera, Manuel Valladares-Ayerbes
Journal: Journal of Clinical Oncology (2012)

e21002 Background: The discovery of KRAS gene as response predictive factor to anti-EGFR antibodies supposed a revolution in the pharmacological management of metastatic colorectal cancer (mCRC) patients (pts), since only KRAS native (WT) pts are possible responders (R) and susceptible to be treated with this targeted therapy. However, the appearance of non-responders (NR) among KRAS WT pts during the administration of anti-EGFR therapy has stimulated the research in additional predictive markers. Here, we explore the putative role of microRNA (miRNA) deregulation as predictive tool of response to anti-EGFR therapy in mCRC pts. Methods: Tissue samples of mCRC were obtained as formalin-fixed paraffin-embedded (FFPE) specimens from the archives of our institution, after obtaining informed consent of pts. Genomic DNA was extracted using Qiaamp DNA mini kit (Qiagen). For the mutational testing of KRAS gene, we use the TheraScreen KRAS PCR kit (DxS, Qiagen). miRNA-containing total RNA was extracted using Tripure (Roche). miRNA expression was analyzed by SYBR-green-based RT-qPCR in a LightCycler 480 (Roche) device using the Human Cancer RT2 miRNA PCR array (SABiosciences, Qiagen). First data analysis was performed with the application provided by supplier (SABiosciences, Qiagen). Bioinformatic analyses were performed in miRBase 18, TargetScanHuman 6.0 and TarBase 6.0 databases. Additional statistical analyses were performed on R 2.14 (R Foundation), SPSS 19 (IBM) and Prism (GraphPad). Results: We analyze 9 primary colon cancer and 3 non-matched normal adjacent (NAT) tissues. Tumor samples corresponded to 6 KRAS WT and 3 KRAS mutated pts. Among KRAS WT pts, 3 had shown response to anti-EGFR antibodies and 3 did not. Samples were analyzed in duplicate for the expression of 88 cancer-related miRNAs. We found 22 miRNAs significantly (p&lt;0.01) upregulated (&gt;4-fold) when comparing KRAS WT NR versus R pts. From these 22 miRNAs, we detected only 6 when we search in databases for experimentally tested or predicted miRNA interactions with KRAS. Conclusions: We found a miRNA signature which could be utilized as response predictive tool for anti-EGFR therapy in mCRC pts. Further analysis will be necessary to establish the performance of this signature.
ASSESSING FRAILTY-ASSOCIATED CHARACTERISTICS AND OUTCOMES IN THE DUAL ANTIPLATELET THERAPY (DAPT) STUDY USING MEDICARE CLAIMS: INSIGHTS FROM THE EXTEND-DAPT STUDY
Authors: Kamil Faridi, Harun Kundi, Jordan B. Strom, Jeptha P. Curtis, Qi Gao, Yang Song, Hector Tamez Aguilar, Laura Mauri, Changyu Shen, Robert W. Yeh
Journal: Journal of the American College of Cardiology (2020)
QIM20-129: Are You Ready? Assessing Readiness to Implement Quality Improvement in Hospitals Participating in a Breast Cancer Collaborative
Authors: Lindsey Kreutzer, Ashley Byerly, Eileen Ngo, Julie K. Johnson, Karl Y. Bilimoria, Anthony D. Yang
Journal: Journal of the National Comprehensive Cancer Network (2020)

"QIM20-129: Are You Ready? Assessing Readiness to Implement Quality Improvement in Hospitals Participating in a Breast Cancer Collaborative" published on 20 Mar 2020 by National Comprehensive Cancer Network.
THE USE OF RITUXIMAB TO TREAT IGG4 RELATED DISEASE INDUCED CARDIOMYOPATHY
Authors: Dantwan Smith, Frank McGrew, John Prather, Christopher Smith, Jennifer Nickol, Thomas Flautt, Theodore Richards, Linnea Lebaron, Dakshin Gangadharamurthy, Likhitesh Jaikumar, Alison Spangler, Wittmann Murphy
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF CARDIAC OUTPUT ESTIMATES BY BIOREACTANCE AND ECHOCARDIOGRAPHY AT REST AND PEAK DOBUTAMINE STRESS TEST IN PATIENTS OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Authors: Shantanu Sengupta, Kunda Mungulmare, Guy MacGowan, Djordje Jakovljevic
Journal: Journal of the American College of Cardiology (2020)
National Toxic Substances Incidents Program — Nine States, 2010–2014
Authors: Natalia Melnikova, Jennifer Wu, Patricia Ruiz, Maureen F. Orr
Journal: MMWR Surveillance Summaries (2020)

CDC summarizes 2010-2014 data from the National Toxic Incidents Program, which collected data on any uncontrolled or illegal acute (lasting <72 hours) release of any toxic substance including chemical, biologic, radiologic, and medical materials.